Concordant ETV6::RUNX1-positive acute lymphoblastic leukemia in monozygotic twins: a case report and review of the literature
-
By
-
Xiaohua Li
-
Cuicui Wang
-
Jianchang Li
-
Chaoyue Liu
-
Weimei Sun
-
Yanjun Zhang
-
Jian Shi
-
June 18, 2026
-
Clinical Scorecard: ETV6::RUNX1-positive acute lymphoblastic leukemia in identical twins: a case study and literature review
At a Glance
| Category | Detail |
|---|
| Condition | Acute Lymphoblastic Leukemia (ALL) |
| Key Mechanisms | ETV6::RUNX1 fusion gene |
| Target Population | Pediatric patients, specifically monozygotic twins |
| Care Setting | Hospital |
Key Highlights
- Both twins diagnosed with acute lymphoblastic leukemia (B-ALL and Pre-B-ALL)
- Positive for ETV6::RUNX1 fusion gene
- Received chemotherapy according to CCLG-ALL-2018 protocol
- Achieved complete remission after treatment
- Continuous complete remission for over 2 years post-treatment
Guideline-Based Recommendations
Diagnosis
- Bone marrow examination and immunophenotyping for ALL diagnosis
Management
- Chemotherapy according to CCLG-ALL-2018 protocol
Monitoring & Follow-up
- Bone marrow minimal residual disease (MRD) assessment
Risks
- Complications including infections, myelosuppression, gastrointestinal symptoms, and liver function abnormalities
Patient & Prescribing Data
Pediatric patients with ETV6::RUNX1-positive ALL
Chemotherapy led to complete remission in both patients
Clinical Best Practices
- Regular follow-up for monitoring remission status
- Prompt management of treatment-related complications
Related Resources & Content
